FRS2 and neoplasm: This patient case highlights that, in addition to patients harbouring FGFR3 hotspot mutations or fusions in their tumour, there is potential for additional UC patients with high expression of FGFR pathway components such as FGFR, ligand and FRS2 to gain benefit from FGFR inhibitor therapy.